menu toggle
As we continue to evolve our brand to Cencora, you will continue to see visual changes. We will be sunsetting amerisourcebergen.com over time and are actively moving content and information over to cencora.com. Please visit cencora.com if you can't find what you are looking for here.

Webinar slides: Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies

By Tasmina Hydery

Xcenda and FormularyDecisions joined AMCP for a live webinar on Tuesday, June 21, 2022 titled, “Navigating Reimbursement and Access Challenges for Novel Cell and Gene Therapies.” 

Cell and gene therapies promise to potentially transform the management of devastating and life-threatening chronic diseases for many patients. However, life sciences companies developing these innovative therapies continue to face reimbursement and patient access challenges.

From these presentation slides, you’ll learn more on: 

  •  A summary of approved and investigational cell and gene therapies in late-stage development 
  • Common reimbursement and access challenges for cell and gene therapies, including payment methodologies, correct coding, and billing 
  • Review an inpatient case study for Yescarta (axicabtagene ciloleucel) and Kymriah (tisagenlecleucel) 

Enter your information to download the webinar slides